Methotrexate composition
A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
1. A Methotrexate composition for oral administration, said composition consisting of a pharmaceutically acceptable salt of Methotrexate, purified water, one or more buffer agents to adjust the pH of the composition, wherein the pH of the composition is 6.25+/−0.15 and the one or more buffer agents have a strength between 2 to 20 millimolar, and one or more agents selected from the group consisting of preserving agents, flavouring compounds, and sweetening agents.
2. The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable salt of Methotrexate used is Methotrexate disodium.
3. The Methotrexate composition according to claim 1 wherein the one or more buffer agents comprise any or any combination of Citric Acid, Citric Acid Monohydrate, Sodium Citrate, Sodium Dihydrogen Phosphate, Disodium Hydrogen Phosphate, Trometamol (Tris), Hydrochloric Acid, Ascorbic Acid, Sodium Ascorbate, any of the abovementioned sodium salts replaced with potassium salts.
4. The Methotrexate composition according to claim 1 wherein the composition comprises two or more buffer agents to form a buffer system.
5. The Methotrexate composition according to claim 4 wherein the two or more buffer agents are any of a Citric Acid-Sodium Citrate Buffer, Citric Acid Monohydrate-Disodium Dihydrogen Phosphate Buffer, Sodium Dihydrogen Phosphate-Disodium Hydrogen Phosphate Buffer, Trometamol (Tris)-Hydrochloric Acid Buffer, Trometamol (Tris)-Citric Acid Buffer, Ascorbic Acid-Sodium Ascorbate Buffer, any of the abovementioned sodium salts replaced with potassium salts.
6. The Methotrexate composition according to claim 1 wherein the preserving agents comprise any or any combination of Sodium Methyl Hydroxybenzoate, Sodium Ethyl Hydroxybenzoate, Sodium Propyl Hydroxybenzoate, Sodium Benzoate or Potassium Sorbate.
7. The Methotrexate composition according to claim 1 wherein the flavouring compounds and sweetening agents comprise Sucralose, Acesulfame K, any other water soluble sweetener or Raspberry Flavour 545742E.
8. The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used is 2.5 mg/5 ml, 5 mg/5 ml, 10 mg/5 ml or in the range of 0.05 mg/1 ml to 20 mg/1 ml.
9. A Methotrexate composition according to claim 1 , said composition consisting of about 3 milliliters purified water, methotrexate disodium quantum satis to about 10.97 milligrams, sodium methyl hydroxybenzoate quantum satis to about 4.80 milligrams, sodium ethyl hydroxybenzoate quantum satis to about 2.40 milligrams, about 25.0 milligrams citric acid monohydrate, about 5.72 milligrams disodium hydrogen phosphate dihydrate, about 10.0 milligrams raspberry flavour 545742E, about 2.5 milligrams sucralose, mixed with additional purified water to a total volume of about 5 milliliters.
10. A Methotrexate composition according to claim 1 , said composition consisting of about 3 milliliters purified water, sodium methyl hydroxybenzoate quantum satis to about 4.80 milligrams free acid, sodium ethyl hydroxybenzoate quantum satis to about 2.40 milligrams free acid, about 5.72milligrams disodium hydrogen phosphate dihydrate, about 6.27 milligrams citric acid monohydrate, about 10.0 milligrams raspberry flavour 545742E, about 2.5 milligrams sucralose, mixed with a solution comprising about 0.375 milliliters purified water and methotrexate disodium quantum satis to about 10.97 milligrams and with additional purified water to a total volume of about 5 milliliters.
11. The Methotrexate composition according to claim 10 , wherein a 10 percent weight/volume solution of disodium hydrogen phosphate dihydrate or 10 percent weight/volume solution of citric acid monohydrate is added quantum satis until the pH of the composition is 6.25+/−0.15.
12. A Methotrexate composition for use as a folic acid antagonist, as an anti-neoplastic agent, an immunosuppressant, an anti-metabolite, or for use in the treatment of neoplastic disease, malignant disease, psoriasis, Crohn's disease, rheumatoid arthritis, polyarthritic forms of active juvenile idiopathic arthritis, juvenile dermatomyositis, vasculitis, uvenlitis, systemic lupus erythematosus, localised scleroderma and sarcoidrosis, said composition consisting of a pharmaceutically acceptable salt of Methotrexate, purified water, one or more buffer agents to adjust the pH of the composition, wherein the pH of the composition is 6+/−0.15 and the one or more buffer agents have a strength between 2 to 20 millimolar, and one or more agents selected from the group consisting of preserving agents, flavouring compounds, and sweetening agents.
13. A method of manufacturing a Methotrexate composition for oral administration, said method consisting of the steps of mixing a pharmaceutically acceptable salt of Methotrexate with purified water until the Methotrexate salt is completely soluble in the purified water to form an aqueous solution, mixing one or more buffer agents into the aqueous solution to adjust the pH of the composition, wherein the pH of the final composition is 6.25+/−0.15 and the one or more buffer agents have a strength between 2 to 20 millimolar, and mixing one or more agents selected from the group consisting of preserving agents, flavouring compounds, and sweetening agents into the aqueous solution.